Breaking News Instant updates and real-time market news.

SNDX

Syndax

$11.11

-0.27 (-2.37%)

, MRK

Merck

$59.76

0.58 (0.98%)

07:02
05/17/18
05/17
07:02
05/17/18
07:02

Syndax reports updated results from Phase 2 ENCORE 601 trial

Syndax Pharmaceuticals (SNDX) announced updated results from multiple cohorts of the ongoing Phase 2 ENCORE 601 trial of entinostat in combination with KEYTRUDA, Merck's (MRK) anti-PD-1 therapy. This data will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting being held June 1-5, 2018 in Chicago, Illinois. ENCORE 601 is a Phase 1b/2 trial evaluating the efficacy and safety of entinostat in combination with pembrolizumab across multiple cohorts of PD-(L)1 treatment-naive and pre-treated cancers, including non-small cell lung cancer, melanoma and microsatellite stable colorectal cancer. Confirmed objective responses with the combination regimen have been observed across all cohorts. Updated data continue to demonstrate a manageable toxicity profile for the entinostat-pembrolizumab combination, with treatment emergent adverse events observed consistent with those previously reported. The ENCORE 601 study also incorporates an extensive biomarker assessment of pre- and on-treatment blood and tumor samples from all patient cohorts with the goal of identifying a patient enrichment strategy that may predict enhanced clinical benefit across various cohorts and, therefore, potentially inform the design of future registration-directed studies.

SNDX

Syndax

$11.11

-0.27 (-2.37%)

MRK

Merck

$59.76

0.58 (0.98%)

  • 21

    May

  • 01

    Jun

  • 05

    Jun

  • 23

    Oct

SNDX Syndax
$11.11

-0.27 (-2.37%)

08/11/17
OPCO
08/11/17
NO CHANGE
Target $29
OPCO
Outperform
Syndax price target raised to $29 from $25 at Oppenheimer
Oppenheimer analyst Hartaj Singh raised his price target for Syndax Pharmaceuticals to $29 saying he remains bullish following the Q2 results and business update. The Encore 601 trial melanoma stage two cohort continues to build on its "impressive" ASCO 2016 data, with full enrollment in Q3, a full quarter ahead of schedule, the analyst tells investors in a research note. He keeps an Outperform rating on Syndax.
01/05/18
RILY
01/05/18
INITIATION
Target $40
RILY
Buy
Syndax initiated with a Buy at B. Riley FBR
B. Riley FBR analyst Madhu Kumar started Syndax Pharmaceuticals with a Buy rating and $40 price target. The analyst sees "highly favorable risk/reward dynamics" for the company's lead asset, entinostat, in breast cancer.
01/05/18
01/05/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Becton Dickinson (BDX) initiated with an Overweight at KeyBanc. 2. Syndax (SNDX) initiated with a Buy at B. Riley FBR. 3. Sutherland Asset Management (SLD) initiated with an Outperform at JMP Securities. 4. Nike (NKE) was assumed with a Buy at Buckingham while Under Armour (UA, UAA) was assumed with a Neutral. 5. Regulus (RGLS) initiated with an Outperform at Leerink. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
05/09/18
NOMU
05/09/18
NO CHANGE
Target $22
NOMU
Buy
Syndax risk/reward positive into data, says Nomura Instinet
Nomura Instinet analyst Christopher Marai sees a positive risk/reward on Syndax Pharmaceuticals into the entinostat readout, expected in Q3. The analyst believes downside is limited on this readout, given expectations and the potential for success on the overall survival endpoint. He calls the stock "significantly undervalued" and keeps a Buy rating on Syndax with a $22 price target.
MRK Merck
$59.76

0.58 (0.98%)

04/25/18
DBAB
04/25/18
NO CHANGE
DBAB
Hold
Merck may need to reassess animal health unit, says Deutsche Bank
While Merck (MRK) describes its animal health unit as a key growth driver and an important part of the company, it remains to be seen whether investors will continue to accept this as a reason for the business to remain within the company, Deutsche Bank analyst Gregg Gilbert tells investors in a research note. He believes the unit is potentially undervalued. Given Zoetis' (ZTS) success as a company and a stock, and Eli Lilly's (LLY) ongoing review of strategic options for its Elanco Animal Health business, Gilbert conducted a preliminary separation analysis of Merck's animal health unit. The analysis suggests that a separation could be meaningfully accretive to earnings. The analyst keeps a Hold rating on Merck.
04/26/18
BMOC
04/26/18
NO CHANGE
Target $70
BMOC
Outperform
Merck price target raised to $70 from $65 at BMO Capital
BMO Capital analyst Alex Arfaei raised his price target on Merck to $70 and kept his Outperform rating, forecasting a "mixed to net-positive" Q1 earnings report. The analyst notes the focus will likely fall on the core Keytruda and Januvia franchises as he raises his peak sales estimate for the former to $13B from $12B after KN-189 data, which he expects to be further supported by discussions at ASCO.
05/10/18
STFL
05/10/18
NO CHANGE
STFL
Hold
Exelixis pullback may create interesting entry point, says Stifel
After Exelixis (EXEL) and partner Roche (RHHBY) announced the Phase 3 IMblaze370 trial did not achieve statistical-significance on the primary efficacy endpoint evaluating the ability of a combination of a MEK inhibitor and anti-PD-L1 to improve overall survival in patients with microsatellite stable metastatic colorectal cancer, Stifel analyst Stephen Willey said he believes attrition in Exelixis shares might create an interesting entry point. The failure of IMblaze370 removes some of Exelixis' longer-term optionality and he expects topics of RCC growth/competition, label expansion, and longer-term cabozantinib exclusivity to remain core to the story going forward, said Willey who has a Hold rating on the stock. Array BioPharma (ARRY) also has Phase 1/2 development collaborations in place with both Bristol-Myers (BMY) and Merck (MRK) evaluating the MEK/PD-1 hypothesis in earlier-lines of MSS mCRC, noted Willey, who said he would "be opportunistic" on any weakness in its shares. He maintains a Buy rating on Array, which is down 5% in pre-market trading.
05/16/18
SPHN
05/16/18
INITIATION
Target $16
SPHN
Overweight
Codexis initiated with an Overweight at Stephens
Stephens analyst Drew Jones started Codexis (CDXS) with an Overweight rating and $16 price target, stating that the company's CodeEvolver platform technology has been sought by pharma partners Merck (MRK), GlaxoSmithKline (GSK) and Nestle (NSRGY) and he expects continued deeper adoption from other major industry players.

TODAY'S FREE FLY STORIES

15:10
08/21/18
08/21
15:10
08/21/18
15:10
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

PSTG

Pure Storage

$22.00

0.2 (0.92%)

15:04
08/21/18
08/21
15:04
08/21/18
15:04
Options
Pure Storage options imply 10.8% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 04

    Sep

  • 12

    Sep

  • 03

    Oct

  • 04

    Oct

  • 05

    Oct

CASY

Casey's General Stores

$116.05

1.33 (1.16%)

15:01
08/21/18
08/21
15:01
08/21/18
15:01
Conference/Events
Casey's General Stores management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 17

    Sep

  • 06

    Nov

RIGL

Rigel Pharmaceuticals

$2.67

0.08 (3.09%)

15:00
08/21/18
08/21
15:00
08/21/18
15:00
Hot Stocks
Rigel's Rodriguez says 'work has just begun' with Tavalisse launch »

In an exclusive interview…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EA

Electronic Arts

$127.21

-0.47 (-0.37%)

15:00
08/21/18
08/21
15:00
08/21/18
15:00
Options
Electronic Arts attracts a bullish option play »

Electronic Arts attracts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 04

    Sep

  • 12

    Sep

  • 12

    Sep

  • 13

    Sep

URBN

Urban Outfitters

$47.40

-0.12 (-0.25%)

14:49
08/21/18
08/21
14:49
08/21/18
14:49
Options
Urban Outfitters options imply 12.9% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

SFIX

Stitch Fix

$34.77

1.92 (5.84%)

14:45
08/21/18
08/21
14:45
08/21/18
14:45
Options
Stitch Fix call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 01

    Oct

ATVI

Activision Blizzard

$69.63

0.7 (1.02%)

14:40
08/21/18
08/21
14:40
08/21/18
14:40
Periodicals
Breaking Periodicals news story on Activision Blizzard »

M Science says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 04

    Sep

  • 12

    Sep

  • 13

    Sep

NURO

NeuroMetrix

$1.26

0.04 (3.28%)

, GSK

GlaxoSmithKline

$41.57

0.25 (0.61%)

14:32
08/21/18
08/21
14:32
08/21/18
14:32
Hot Stocks
NeuroMetrix receives $3.8M milestone payment under its pact with GSK »

NeuroMetrix (NURO)…

NURO

NeuroMetrix

$1.26

0.04 (3.28%)

GSK

GlaxoSmithKline

$41.57

0.25 (0.61%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Aug

14:30
08/21/18
08/21
14:30
08/21/18
14:30
General news
Canada Retail Sales Preview »

Canada Retail Sales…

14:25
08/21/18
08/21
14:25
08/21/18
14:25
General news
Treasury Option Action: more bond positioning »

Treasury Option Action:…

MDT

Medtronic

$95.02

4.96 (5.51%)

14:20
08/21/18
08/21
14:20
08/21/18
14:20
Recommendations
Medtronic analyst commentary  »

Medtronic momentum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 23

    Aug

  • 05

    Sep

  • 12

    Sep

MS

Morgan Stanley

$48.75

0.48 (0.99%)

14:20
08/21/18
08/21
14:20
08/21/18
14:20
Options
Mega option block in Morgan Stanley »

Mega option block in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Sep

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
08/21/18
08/21
14:17
08/21/18
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RIGL

Rigel Pharmaceuticals

$2.65

0.06 (2.32%)

14:16
08/21/18
08/21
14:16
08/21/18
14:16
Hot Stocks
Rigel CEO says impact of any Trump policy still unclear »

In an exclusive interview…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
08/21/18
08/21
14:16
08/21/18
14:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$339.67

11.92 (3.64%)

, AAPL

Apple

$216.73

1.25 (0.58%)

14:07
08/21/18
08/21
14:07
08/21/18
14:07
Periodicals
Netflix testing how to bypass iTunes billing in 33 countries, TechCrunch says »

Netflix (NFLX) is…

NFLX

Netflix

$339.67

11.92 (3.64%)

AAPL

Apple

$216.73

1.25 (0.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

UAL

United Continental

$86.00

0.765 (0.90%)

14:06
08/21/18
08/21
14:06
08/21/18
14:06
Periodicals
United's Kirby sees average airfares improving, Bloomberg reports »

As U.S. rivals offer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

APO

Apollo Global

$34.44

0.22 (0.64%)

, BX

Blackstone

$36.48

-0.32 (-0.87%)

14:04
08/21/18
08/21
14:04
08/21/18
14:04
Periodicals
PE firms eyeing acquisitions of local TV assets, CNBC reports »

Apollo Global (APO),…

APO

Apollo Global

$34.44

0.22 (0.64%)

BX

Blackstone

$36.48

-0.32 (-0.87%)

NXST

Nexstar

$80.25

1.05 (1.33%)

TRCO

Tribune Media

$35.98

0.91 (2.59%)

SBGI

Sinclair Broadcast

$29.30

0.55 (1.91%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

  • 06

    Sep

UAL

United Continental

$86.32

1.085 (1.27%)

14:00
08/21/18
08/21
14:00
08/21/18
14:00
Options
Heavy call activity in UAL as shares take off »

Heavy call activity in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

RIGL

Rigel Pharmaceuticals

$2.66

0.07 (2.70%)

13:52
08/21/18
08/21
13:52
08/21/18
13:52
Hot Stocks
Rigel's Rodriguez says physician response to Tavalisse 'very positive' »

In an exclusive interview…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JCI

Johnson Controls

$39.84

1.11 (2.87%)

13:50
08/21/18
08/21
13:50
08/21/18
13:50
Options
Notable call spread in Johnson Controls as shares rally »

Notable call spread in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$287.20

1.52 (0.53%)

, SPX

S&P 500

$0.00

(0.00%)

13:46
08/21/18
08/21
13:46
08/21/18
13:46
Periodicals
Michael Cohen enters plea deal with federal prosecutors, ABC News says »

Tom Llamas, ABC…

SPY

SPDR S&P 500 ETF Trust

$287.20

1.52 (0.53%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GME

GameStop

$16.35

0.5 (3.15%)

13:45
08/21/18
08/21
13:45
08/21/18
13:45
Options
GameStop call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:40
08/21/18
08/21
13:40
08/21/18
13:40
General news
FOMC minutes preview: »

FOMC minutes preview: the…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.